Introduction/Background The uterine sarcoma represents 1 to 5% of malignant tumors of the uterus.

Distribution 1. T. mixed epithelial and mesenchymal elements (T Mixed müllerian) (50–60 %): represented by the carcinosarcoma, adenosarcoma; 2. leiomyosarcoma (35%); 3. endometrial stromal sarcoma (ESS) (chorion cytogene low grade Bad prognosis except SBS 10%): low grade, and undifferentiated. Improved Surgery of the primary tumor and metastasis is essential. Place of the adjuvant chemotherapy remains has only the local control. Sensitivity differently according under histological type. Place determined of targeted therapeutic to define: the trabectidine.

Methodology The retrospective study of 17 cases of uterine sarcoma support in the medical oncology and surgical department at CPMC during the period between 2011–2018.

Results average age of diagnosis: 51 years. The diagnosis been done on the histological examination revealed to the operating room and post-operative. Three varieties: 10 cases of leiomyosarcoma, 3 cases of carcinosarcoma, 4 cases of endometrial stromal sarcoma (ESS) (chorion cytogene of the endometrial).The stage IV of the tumor was found in 50% of tumors and 25% for the stage IA. The prognosis is closely related to the stage of the tumor. The treatment was essentially a radical surgery in 5 cases, 12 cases have beneficed of chemotherapy, in cases of recurrence or metastasis. The protocols used concurrent chemoradiotherapy (CCRT) has been performed in patient presenting a carcinosarcoma. The answer: Total response (7 cases); Partiel response (2 cases); Stable disease (4 cases); failed (4 cases). Follow up: nine patients alive in remission, 4 patients died, 4 living patients in recurrence.

Conclusion the uterine sarcoma is a tumor of bad prognosis significance, the surgical of the primary tumor and metastases is essential; the chemotherapy is reserved in the event of a recurrence or metastatic. We report in this study, the Algerian experience in support of uterine sarcomas.